Kunj Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
- Revenue Growth -12.87%
- Profit Growth 1.49%
- Ebitda 9.10%
- Net Worth 41.74%
- Total Assets -0.06%
About Kunj Pharma
Kunj Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 May 2015 (Nine years and nine months 27 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Raj Jindal and Karan Jindal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397DL2015PTC279683
- Company No.
279683
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Kunj Pharma Private Limited offer?
Kunj Pharma Private Limited offers a wide range of products and services, including Animal Medicines & Health Care, Veterinary Bolus, Brain & Nervous System Drugs, Immunomodulator Drugs, Veterinary Medicines, Sexual Wellness Products, Fertility Enhancer, Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication, Veterinary Injections.
Who are the key members and board of directors at Kunj Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Jindal  | Director | 01-May-2015 | Current |
| Karan Jindal | Director | 01-May-2015 | Current |
Financial Performance of Kunj Pharma.
Kunj Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 12.87% decrease. The company also saw a slight improvement in profitability, with a 1.49% increase in profit. The company's net worth Soared by an impressive increase of 41.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kunj Pharma?
In 2020, Kunj Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Central Bank Of India : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Jul 2015 | Central Bank Of India | ₹5.00 M | Open |
How Many Employees Work at Kunj Pharma?
Unlock and access historical data on people associated with Kunj Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kunj Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kunj Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
